亚太地区病毒样颗粒市场预测至 2028 年 - 按产品类型(肝炎、癌症/HPV 和戈谢病)、来源(酵母、昆虫细胞、植物等)和应用(疫苗)划分的 COVID-19 影响和区域分析和治疗)

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028


No. of Pages: 125    |    Report Code: TIPRE00026817    |    Category: Life Sciences

Asia Pacific Virus-like Particles Market

亚太地区病毒样颗粒市场预计将从 2021 年的1,018.83 亿美元增长至1,769.02 美元到 2028 年将达到 100 万;

预计 2021 年至 2028 年复合年增长率为 8.2%。

< /h3>医疗保健市场的各个参与者和研究组织都积极参与产品创新和开发。使用病毒样颗粒是生物制药行业中使用的一种新兴方法。由于病毒样颗粒缺乏病毒成分,因此它们比实际的病毒成分更容易处理。 VLP 可用于辅助药物输送、成像、免疫治疗和治疗诊断。例如,根据 NCBI 2020 年 6 月发表的一项研究,VLP 可以纳米颗粒的形式用于光热疗法、PET 和 CT 成像、MRI 造影剂载体、光学成像、炎症和自身免疫性疾病疫苗等应用,癌症免疫疗法和小分子药物输送(在癌症治疗中)。因此,VLP 的此类潜在应用预计将在预测期内为市场参与者提供增长机会。

 

根据国际货币基金组织 (IMF) 报告预计 2020 年亚太地区的增长将继续停滞在 0%。这是近 60 年来最糟糕的增长表现,涉及全球金融危机 (4.7%) 和亚洲金融危机 (1.3%)。韩国的下调幅度较大,幅度为 3.5%,但由于澳大利亚、新西兰和泰国将长期停产时间降至 9%,因此似乎可以应对冠状病毒的缓慢传播。由于全球旅游业关闭,以及澳大利亚大宗商品价格下跌,这些国家受到了沉重打击。目前正在开发 COVID-19 疫苗的亚太地区包括韩国、中国、日本、泰国和越南。其中,中国有15种疫苗,印度和韩国有3种疫苗,日本有2种疫苗,泰国和越南有1种疫苗。其中疫苗包括10种灭活疫苗、6种蛋白亚单位疫苗、7种病毒载体疫苗、6种核酸疫苗。此外,推广安全、公平、有效的疫苗是亚太地区的首要任务。根据亚洲开发银行的报告,2020年12月,亚洲开发银行(ADB)与亚太疫苗获取机制(APVAX)启动了一项90亿美元的疫苗计划,将为发展中成员提供快速和公平的支持国家(发展中成员体)采购和提供有效且安全的 COVID-19 疫苗。通过疫苗接种,可以打破病毒传播链,挽救生命,减轻疫情的负面影响。

 

随着新冠病毒的出现,功能和技术,供应商可以吸引新客户并扩大其在新兴市场的足迹。这一因素可能会推动亚太地区病毒样颗粒市场的发展。预计亚太地区病毒样颗粒市场在预测期内将以良好的复合年增长率增长。

 

 亚太地区类病毒颗粒市场收入及预测至 2028 年(百万美元)

 

亚太地区病毒样颗粒市场细分

 

亚太地区病毒样颗粒市场 –按产品类型

  • 肝炎
  • 癌症/HPV
  • 戈谢病

亚太地区病毒样颗粒市场 -按来源

  • 酵母
  • 昆虫细胞
  • 植物
  • 其他

亚太类病毒颗粒市场 -按

应用

  • 疫苗
  • 治疗

亚太地区病毒样颗粒市场 -按

国家

  • 中国
  • 日本
  • 印度
  • 澳大利亚
  • 韩国
  • 亚太地区其他地区    

亚太地区病毒样颗粒市场 –提及的公司

  • 默克公司                   ;                  &n公共服务提供商;      
  • 葛兰素史克公司
  • 辉瑞公司;                  &n公共服务提供商;                         ;           
  • 赛诺菲                          ;                     ;               
  • <印度血清研究所列兵。                        
  • 巴拉特生物科技            ;                  &n公共服务提供商;            
  • LG化学                       ;                     ;              
  • 万泰生物制药


Asia Pacific Virus-like Particles Strategic Insights

Strategic insights for Asia Pacific Virus-like Particles involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-virus-like-particles-market-strategic-framework.webp
Get more information on this report

Asia Pacific Virus-like Particles Report Scope

Report Attribute Details
Market size in 2021 US$ 1,018.83 Million
Market Size by 2028 US$ 1,769.02 Million
Global CAGR (2021 - 2028) 8.2%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By 产品类型
  • 肝炎
  • 癌症/HPV
  • 戈谢病
By 来源
  • 酵母
  • 昆虫细胞
  • 植物
By 应用
  • 疫苗和治疗学
Regions and Countries Covered 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
Market leaders and key company profiles
  • Merck & Co., Inc.
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • BHARAT BIOTECH
  • LG Chem
  • Wantai BioPharm
  • Get more information on this report

    Asia Pacific Virus-like Particles Regional Insights

    The regional scope of Asia Pacific Virus-like Particles refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-virus-like-particles-market-geography.webp
    Get more information on this report

    The List of Companies - Asia Pacific Virus-like Particles Market

    1. Merck & Co., Inc.                                                       
    2. GlaxoSmithKline plc.                                                
    3. Pfizer Inc.                                                                    
    4. Sanofi                                                                         
    5. Serum Institute of India Pvt. Ltd.                           
    6. BHARAT BIOTECH                                                      
    7. LG Chem                                                                     
    8. Wantai BioPharm
    Frequently Asked Questions
    How big is the Asia Pacific Virus-like Particles Market?

    The Asia Pacific Virus-like Particles Market is valued at US$ 1,018.83 Million in 2021, it is projected to reach US$ 1,769.02 Million by 2028.

    What is the CAGR for Asia Pacific Virus-like Particles Market by (2021 - 2028)?

    As per our report Asia Pacific Virus-like Particles Market, the market size is valued at US$ 1,018.83 Million in 2021, projecting it to reach US$ 1,769.02 Million by 2028. This translates to a CAGR of approximately 8.2% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Virus-like Particles Market report typically cover these key segments-

  • 产品类型 (肝炎, 癌症/HPV, 戈谢病)
  • 来源 (酵母, 昆虫细胞, 植物)
  • 应用 (疫苗和治疗学)
  • What is the historic period, base year, and forecast period taken for Asia Pacific Virus-like Particles Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Virus-like Particles Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in Asia Pacific Virus-like Particles Market?

    The Asia Pacific Virus-like Particles Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Merck & Co., Inc.
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • BHARAT BIOTECH
  • LG Chem
  • Wantai BioPharm
  • Who should buy this report?

    The Asia Pacific Virus-like Particles Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Virus-like Particles Market value chain can benefit from the information contained in a comprehensive market report.